UBS raises IDEXX Laboratories stock price target on strong international growth

UBS raised its price target on IDEXX Laboratories (IDXX) to $700, citing strong international growth and a beat-and-raise quarter. The company reported 11.87% revenue growth and a 62.72% gross margin. Despite a 20% stock surge, UBS maintains a Neutral rating, noting potential overvaluation.

Original reporting
Published Nov 3, 2026, 9:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IDXX
Bullish
high confidence
Mentioned
$IDXX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IDXXBullishMed
01

Why it matters

The upgrade could attract new buying interest and sustain the recent 20% price gain.

02

Market read

Earnings beat and analyst upgrade provide fresh bullish catalyst for IDXX.

03

What to watch

Potential pricing pressure from a looming price war in the companion animal market.

Relevance 8/10Novelty 8/10Timing: post‑market reaction

Background

IDXX reported Q3 results that beat expectations, prompting UBS to raise its price target.

Company-level read

Ticker impact

$IDXXBullishHigh confidence
Context

UBS raised IDXX price target to $700 after the company posted Q3 earnings beat (EPS $3.96, revenue $1.21B) and 20% share jump.

Expected impact

upward pressure as the market prices in the higher target and earnings beat.

Evidence & confidence

The price‑target increase reflects fresh bullish expectations; earnings beat confirms earnings momentum.

Market effects

Strong performance may lift the veterinary diagnostics sector.

U.S. consumer discretionary sentiment reinforced.

Limited to U.S. and sector investors.

Counterpoint

The high P/E of 47 may suggest overvaluation despite the upgrade.

Key entities

  • UBS

    Raised price target to $700, maintaining Neutral rating.

Related articles

$IDXXHighAI 8/10

IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook

IDEXX Laboratories reported Q3 2026 earnings, raising its full-year organic growth outlook to nearly 10% despite challenges. US clinic visits declined 1.8%, and macro pressures impacted puppy/kitten adoptions. CoVet acquisition is expected to dilute EPS by $0.13 in 2026. Global Rapid Assay revenues grew 1% organically. The company attributed growth to innovations, record instrument placements, and higher-quality visits.